SCHEMBL5139322

SCHEMBL5139322

Cc1cc2oc(=O)c([N+](=O)[O-])c(O)c2cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
GRIN3A Q8TCU5 1/20 0.46
NQO1 P15559 3/20 0.46
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PIM1 P11309 1/20 0.42
DYRK1A Q13627 1/20 0.42
PIM3 Q86V86 1/20 0.42
PIM2 Q9P1W9 1/20 0.42
MCL1 Q07820 2/20 0.42
CA12 O43570 1/20 0.42
CA9 Q16790 1/20 0.42
MAPK1 P28482 1/20 0.42
MAPT P10636 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11390970 0.88 NQO1 (0.58) NQO1ALDH1A1PIM1DYRK1APIM3
SCHEMBL11848522 0.87 NQO1 (0.56) NQO1ALDH1A1PIM1DYRK1APIM3
SCHEMBL11848511 0.87 NQO1 (0.56) NQO1ALDH1A1PIM1DYRK1APIM3
SCHEMBL11839742 0.82 NQO1 (0.48) NQO1ALDH1A1HPGDSMN1; SMN2PIM1
SCHEMBL11843876 0.81 NQO1 (0.50) NQO1ALDH1A1HPGDSMN1; SMN2PIM1
SCHEMBL11854700 0.80 NQO1 (0.49) NQO1HPGDPIM1DYRK1APIM3
SCHEMBL11839510 0.79 NQO1 (0.44) NQO1ALDH1A1HPGDSMN1; SMN2MCL1
SCHEMBL6190126 0.78 NQO1 (0.58) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL5085550 0.78 MAPK1 (0.51) NQO1ALDH1A1PIM1DYRK1APIM3
SCHEMBL11848821 0.78 GRIN2D (0.55) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007115181-A9 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEM CO (US) 2008-04-03 WO disclosed
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof EASTMAN CHEMICAL COMPANY 2007-11-01 US disclosed
WO-2007115181-A2 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEMICAL COMPANY (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof ABCC4, NCOA4, NR4A3 GRIN2D 1932/4885GRIN3B 862/4885GRIN1 1041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.